Biotech AI startup Unlearn adds $15 million and OpenAI CTO to board – ET HealthWorld


Bangalore: Unlearn.AI, which has built a machine learning platform that profiles “digital twins” of patients in clinical trials, has raised $15 million to expand partnerships and speed regulatory approval, the company told Reuters on Tuesday. investment of radical companies and Wittington Enterprises valued the startup at $265 million, the company said.

Look Murati, CTO of Microsoft-backed OpenAI, joins the startup’s board. “The Unlearn team is working on AI applications that have incredible potential to revolutionize healthcare, diagnosis and treatment,” Murati told Reuters.

While generative AI is known for creating content like text, images, and even computer code, Unlearn uses it to build digital twins to speed up clinical drug trials through its neural networks.

If successful, Unlearn’s software could lower costs for drug developers by reducing the number of enrollments needed for clinical trials by replacing patients receiving a placebo.

The funding raised by Unlearn came after it won approval from the European Medicines Agency (EMA) in September for using its AI-powered approach to run smaller, faster clinical trials and struck several multi-million dollar deals with pharmaceutical companies, including Merck. San Francisco-based Unlearn is focused on a relatively new application of generative AI. The technology, in which AI learns to take action from previous data, has become widely known through applications including the OpenAI virus. chatbot ChatGPT. By collecting patient data from research studies, the Unlearn platform calculates a twin for each patient in a clinical trial and fills the control arm of the research with these twins.

With a focus on Phase III clinical trials, charles fisher, CEO of Unlearn, said that getting approvals from regulators, including the US Food and Drug Administration, is critical to commercializing the technology to global drugmakers. “For us, the top priority on the regulatory front is partnering with drugmakers to conduct trials and set a precedent,” Fisher said.

  New diabetes remission clinic uses advanced algorithms, machine learning to tackle disease - ET HealthWorld

Unlearn has raised a total of $85 million from investors including information partners8VC and mubadala companies.



Source link

Leave a Comment